Patents by Inventor Scott A. Oakes

Scott A. Oakes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11649237
    Abstract: Provided herein, inter alia, are substituted imidazo[1,5-?]pyrazine compounds, compositions and methods for treating or preventing an IRE1?-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 16, 2023
    Assignees: Optikira LLC, The Regents of the University of California
    Inventors: Richard M. Keenan, Bradley J. Backes, Dustin J. Maly, Charles Reynolds, Ben Whittaker, Jamie Knight, Jonathan Mark Sutton, George Hynd, Feroz R. Papa, Scott A. Oakes
  • Patent number: 11613544
    Abstract: Described herein, inter alia, are certain substituted imidazo[1,5-a]pyrazines of formula (I) and methods of using the same for modulating the activity of Ire1.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 28, 2023
    Assignees: The Regents of the University of California, University of Washington Through Its Center For Commercialization
    Inventors: Bradley J. Backes, Dustin J. Maly, Scott A. Oakes, Feroz R. Papa, Gayani Perera, Likun Wang
  • Publication number: 20210155626
    Abstract: Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1.
    Type: Application
    Filed: September 24, 2020
    Publication date: May 27, 2021
    Inventors: Bradley J. Backes, Dustin J. Maly, Scott A. Oakes, Feroz R. Papa, Gayani Perera, Likun Wang
  • Publication number: 20200354367
    Abstract: The present invention provides novel compounds, compositions and methods for treating or preventing an IRE1?-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    Type: Application
    Filed: August 31, 2018
    Publication date: November 12, 2020
    Inventors: Richard M. Keenan, Bradley J. Backes, Dustin J. Maly, Charles Reynolds, Ben Whittaker, Jamie Knight, Jon Sutton, George Hynd, Feroz R. Papa, Scott A. Oakes
  • Patent number: 10822340
    Abstract: Described herein, inter alia, are certain substituted imidazolopyrazines of formula (I) and methods of using the same for modulating the activity of Ire1.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: November 3, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Bradley J. Backes, Dustin J. Maly, Scott A. Oakes, Feroz R. Papa, Gayani Perera, Likun Wang
  • Publication number: 20190084989
    Abstract: Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1.
    Type: Application
    Filed: October 2, 2018
    Publication date: March 21, 2019
    Inventors: Bradley J. Backes, Dustin J. Maly, Scott A. Oakes, Feroz R. Papa, Gayani Perera, Likun Wang
  • Patent number: 10131668
    Abstract: Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1 using for example, substituted imidazopyrazine compounds.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: November 20, 2018
    Assignees: The Regents of the University of California, University of Washington Through Its Center For Commercialization
    Inventors: Bradley J. Backes, Dustin J. Maly, Scott A. Oakes, Feroz R. Papa, Gayani Perera, Likun Wang
  • Publication number: 20170165259
    Abstract: Described herein, inter alia, are combined compositions of an Ire1 kinase modulating compound and an Ire1 ribonuclease modulating compound and methods of using the same.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 15, 2017
    Inventors: Dustin J. MALY, Bradley J. Backes, Scott A. Oakes, Feroz R. Papa, Rajarshi Ghosh, Likun Wang
  • Publication number: 20160024094
    Abstract: Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1.
    Type: Application
    Filed: March 26, 2015
    Publication date: January 28, 2016
    Inventors: Bradley J. Backes, Dustin J. Maly, Scott A. Oakes, Feroz R. Papa, Gayani Perera, Likun Wang